Prescription Medicines
Daimit Tab.
- Product Category
- Diabetes treatment
- Active Ingredients
- metformin hydrochloride
- Appearance
- A white, round, film-coated tablet.
- Reimbursement Code
- 648100330
01 / 02
1. Composition and Strength
1 tablet
- Active ingredient: Metformin hydrochloride (EP)----500mg
- Additives: Methacrylic acid/ethyl acrylate copolymer (Eudragit L30D-55), triethyl citrate, povidone, magnesium stearate
2. Effectiveness
• Treatment of type 2 diabetes patients whose blood sugar levels are inadequately controlled through diet and exercise therapy. (Especially in overweight diabetic patients)
In adults, this drug can be used as monotherapy or in combination with other oral hypoglycemic agents or insulin.
• In children over 10 years of age and growing adolescents, this drug can be used as monotherapy or in combination with insulin.
3. Dosage and dosage
adult
The administered dose should be determined for each individual based on drug effectiveness and tolerability, and should not exceed the recommended maximum daily dose.
This drug must be administered at a low dose in order to reduce adverse reactions in the gastrointestinal tract and confirm the minimum dose necessary for proper blood sugar control. Administer 500 mg 2-3 times a day, once with meals. The dosage is gradually increased by 500 mg every week, and when taking up to 2000 mg, it is usually divided into two times a day, in the morning and evening. If the dose exceeds 2000 mg, it can be divided into 3 doses per day and administered with meals, up to a maximum of 2550 mg per day.
When starting medication and adjusting the dose, fasting blood sugar should be measured to measure the therapeutic response to this drug and to confirm the minimum effective dose. The concentration of glycated hemoglobin in the blood should be measured at approximately 3-month intervals.
The treatment goal of this drug is to reduce fasting blood sugar and blood glycated hemoglobin concentration to normal or close to normal levels by administering it at the minimum effective dose when administered as monotherapy or in combination with sulfonylureas or insulin.
In general, if a patient whose blood sugar is controlled through diet alone temporarily loses control of blood sugar, a short-term administration of this drug may be sufficient to achieve sufficient effect.
Children and adolescents
This medicine can be used in children over 10 years of age or growing adolescents.
The typical starting dose is 500 milligrams once daily, administered during or after a meal.
After a week, blood sugar levels should be measured and the dosage adjusted. Gastrointestinal side effects can be improved with gradual dose increase. The maximum daily dose is 2000mg. Divide the dose into 2 to 3 doses.
patients with renal impairment
This drug can be used by adjusting the dose as follows among patients with stage 3a moderate renal impairment (creatinine clearance [CrCl] 45≤~<60ml/min or glomerular filtration rate (GFR) 45≤~<60mL/min/1.73㎡) who are not accompanied by other symptoms that may increase the risk of lactic acidosis.
- The starting dose is 500mg or 850mg once a day. The maximum daily dose is 1000 mg, divided into two doses. Renal function should be closely monitored every 3-6 months. If creatinine clearance or glomerular filtration rate decreases below 45ml/min or 45ml/min/1.73㎡, administration of this drug should be discontinued immediately.
4. Precautions for use
1. Warning
It may cause severe lactic acidosis or hypoglycemia. Cases of death due to lactic acidosis have been reported.
2. Do not administer to the following patients.
1) Patients with moderate (stage3b) and severe renal impairment (creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.73m2), acute conditions that may affect renal function such as dehydration, serious infection, cardiovascular collapse (shock), acute myocardial infarction, and sepsis.
2) Patients with acute and unstable heart failure
3) Patients receiving tests that involve intravenous administration of radioiodine contrast material (e.g. intravenous urography, intravenous cholangiography, angiography, computed tomography using contrast media, etc.) (can cause acute renal failure, and are associated with lactic acidosis in patients receiving this drug. Therefore, among patients scheduled for such tests, if the glomerular filtration rate is >60ml/min/1.73m2, at least at the time of the test or in advance The drug must be discontinued, and re-administration is not possible within 48 hours. In patients with moderate renal impairment (glomerular filtration rate 45 to 60 ml/min/1.73 m2), re-administration is not possible within 48 hours after renal function is re-evaluated. Treatment is resumed only after this.)
4) Patients with a history of hypersensitivity to this drug or biguanide drugs
5) Patients with acute or chronic metabolic acidosis, including type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis [Type 1 diabetes and diabetic ketoacidosis are treated with insulin.]
6) Diabetic precoma
7) In patients with severe infections or severe traumatic systemic disorders, treatment with this drug should be temporarily stopped and treatment should be restarted when the patient's oral intake is restored and renal function is found to be normal.
8) In the case of surgical procedures (excluding minor surgeries where there are no restrictions on food and fluid intake), this drug should be temporarily stopped 48 hours before surgery, and treatment should be restarted at least 48 hours after renal function is confirmed to be normal.
9) Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal dysfunction
10) Hepatic dysfunction (since impaired liver function is associated with some cases of lactic acidosis, administration of this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease), pulmonary infarction, patients with severe pulmonary dysfunction and other conditions prone to hypoxemia, excessive alcohol intake, and patients with gastrointestinal disorders such as dehydration, diarrhea, and vomiting.
11) Pregnant women at risk of placental insufficiency, preeclampsia, and intrauterine growth retardation (refer to section 7. Administration for pregnant women)
3. Administer with caution to the following patients:
(There is a possibility of lactic acidosis and hypoglycemia.)
1) Irregular meals, insufficient meal intake
2) Intense muscle exercise
3) Patients taking interacting drugs
4. Adverse reactions
1) Lactic acidosis: Lactic acidosis is very rare but serious, and is a metabolic complication that occurs due to accumulation of this drug during treatment. In 50% of cases it occurs, it is fatal. Lactic acidosis occurs frequently in acute renal dysfunction, cardiopulmonary disease, and sepsis. Lactic acidosis may occur when there is significant tissue hypoperfusion and hypoxia and in conjunction with pathophysiological conditions, including diabetes. Lactic acidosis is characterized by increased blood lactic acid concentration (over 5 mmol/L), decreased blood pH, electrolyte imbalance with increased difference between anions, and increased lactic acid/pyruvate ratio. If this drug is believed to be the cause of lactic acidosis, the blood concentration of this drug is generally found to exceed 5 μg/mL.
There are very few reports of the development of lactic acidosis in patients receiving this drug (approximately 0.03 cases per 1,000 patients per year, and approximately 0.015 fatal cases per 1,000 patients per year). The reported cases primarily occurred in diabetic patients with significantly reduced renal function, including intrinsic renal disease and renal hypoperfusion, in conditions such as multiple medical and surgical problems and combined administration of many drugs. The risk of lactic acidosis increases with the degree of renal function decline and the patient's age.
In addition, this drug should be discontinued immediately if symptoms related to hypoxia, dehydration, or sepsis appear. If liver function is impaired, the ability to excrete lactic acid may be significantly reduced, so this drug is generally not administered to patients with clinical or laboratory findings of liver disease. Since alcohol may cause this drug to affect lactic acid metabolism, acute or chronic excessive intake of alcohol should be avoided while taking this drug.
The onset of lactic acidosis is sometimes difficult to distinguish and is accompanied by nonspecific symptoms such as malaise, myalgia, dyspnea, asthenia, and abdominal pain. If acidosis becomes more severe, a drop in body temperature, hypotension, and resistant bradyarrhythmia may occur. Patients and doctors should be aware of the importance of these symptoms, and patients should notify their doctors immediately if these symptoms occur. Serum electrolytes, ketones, blood sugar, blood pH (<7.35), lactic acid concentration, and blood concentration of this drug may also be useful in confirming lactic acidosis. Additionally, if there is a high suspicion of lactic acidosis, necessary measures are taken without expecting a lactic acid measurement result. In particular, be careful because lactic acidosis is likely to occur when the initial dose is increased. Gastrointestinal symptoms are common in the early stages of treatment once the patient has stabilized on a specific dose of this drug, but later gastrointestinal symptoms may be due to lactic acidosis or another serious illness.
Fasting venous plasma lactate concentrations above the upper limit of normal but below 5 mmol/L in patients receiving this drug do not indicate impending lactic acidosis and may be due to other mechanisms such as poorly controlled diabetes or obesity, excessive physical activity, or technical problems in handling the specimen. Lactic acidosis should be suspected in diabetic patients presenting with metabolic acidosis without evidence of ketoacidosis (ketonuria and ketonemia).
Lactic acidosis is a medical emergency requiring hospitalization. If lactic acidosis occurs in a patient taking this drug, the drug should be discontinued immediately and general supportive treatment should be administered immediately. Since the drug is dialyzable (clearance up to 170 mL/min in good hemodynamic conditions), immediate hemodialysis is recommended to normalize acidosis and remove accumulated drug. This treatment sometimes results in immediate symptom improvement and recovery.
2) Digestive system: Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal distension, loss of appetite, indigestion, constipation, abdominal pain) are the most common reactions that occur when taking this drug, and especially in the early stages of treatment, they occur about 30% more frequently in the group administered with this drug alone than in the placebo administered group. These symptoms are usually temporary and will disappear on their own while treatment continues. Sometimes, a temporary dose reduction may be useful. In clinical trials, approximately 4% of patients discontinued this drug due to gastrointestinal reactions.
Since gastrointestinal symptoms occur in a dose-related manner during the initial phase of treatment, they can be reduced by gradually increasing the dose or by administering this drug with meals.
Severe diarrhea and/or vomiting may cause dehydration and prerenal azotemia and should be temporarily discontinued under these conditions. In patients who have been stabilized on this drug, non-specific gastrointestinal symptoms may not be due to treatment but may be due to concurrent disease or lactic acidosis.
3) Sensory system: During the initial stage of treatment, approximately 3% of patients complain of an unpleasant or metallic taste, which usually disappears gradually.
4) Skin: A rash may occur, so discontinue administration in this case.
5) Blood system: In rare cases, anemia, decreased white blood cells, and decreased platelets may occur. Vitamin B12 deficiency is common.
6) Liver: Occasionally liver dysfunction may occur.
7) Hypoglycemia: In rare cases, severe delayed hypoglycemia may occur.
8) Adverse reactions in children: Adverse reactions reported in clinical trials in which metformin was administered to a small pediatric cohort of patients aged 10 to 16 years for 1 year, as well as in published and post-marketing surveillance results, were similar to those reported in adults in terms of their characteristics and severity.
5. General precautions
1) Monitoring of renal function: This drug is mostly excreted by the kidneys, and the risk of accumulation of this drug and lactic acidosis increases depending on the degree of renal function impairment. Glomerular filtration rate should be evaluated before starting treatment and periodically thereafter. Patients with normal renal function should have a renal function test checked at least once a year. Patients with a creatinine clearance lower than normal and the elderly should have a renal function test performed at least 2 to 4 times a year. If the creatinine clearance rate is <45ml/min (glomerular filtration rate <45ml/min/1.73m2), discontinue treatment with this drug. Special caution is needed in situations that may result in rapid renal function impairment, such as when there are symptoms of dehydration (severe or persistent vomiting or diarrhea) or when starting medications that affect renal function (such as antihypertensive drugs or diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs)). In these acute situations, metformin should be discontinued immediately and temporarily.
2) Diabetes-like symptoms: Consider application only to patients with an established diagnosis of diabetes. Be aware that in addition to diabetes, there are diseases with diabetes-like symptoms such as abnormal glucose tolerance and positive urine glucose (nephrogenic diabetes, geriatric glucose metabolism abnormalities, thyroid dysfunction, etc.).
3) Adjustment during administration: In cases where administration is no longer necessary, when a reduction is necessary, or when the effect becomes ineffective or insufficient due to the patient's deterioration, complications of infection, etc., pay attention to meal intake, weight change, blood sugar level, presence or absence of infection, etc., and pay attention to whether to continue administration, dosage, and selection of drug.
4) Hypoxic state: Cardiovascular collapse (shock) of any cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxia are associated with lactic acidosis and may cause prerenal azotemia. If this occurs in a patient receiving treatment with this drug, administration of this drug should be discontinued immediately.
5) Cardiac function: Patients with heart failure have a higher risk of hypoxia and decreased renal function. For patients with stable chronic heart failure, metformin can be administered with regular monitoring of heart and kidney function.
6) Alcohol intake: Alcohol is known to increase the effect of this drug on lactic acid metabolism. Therefore, acute or chronic excessive intake of alcohol should be avoided while taking this medicine.
7) Vitamin B12 level: It is recommended to monitor serum vitamin B12 level annually. The risk of low vitamin B12 levels increases in patients with higher metformin doses, longer treatment duration, and/or with risk factors known to cause vitamin B12 deficiency.
8) Changes in controlled diabetic patients: If a patient whose type 2 diabetes was previously well controlled with this drug develops abnormal laboratory findings or clinical disease (especially vague and poorly defined disease), the patient should be immediately evaluated for the development of ketoacidosis or lactic acidosis. Serum electrolytes, ketones, and blood sugar levels are tested, and if necessary, blood pH, lactate, pyruvate, and drug levels are tested. If any form of acidosis appears, immediately stop administering this drug and take other appropriate and correct measures.
9) Hypoglycemia: Hypoglycemia does not occur in patients who take this drug alone under normal use conditions, but occurs when caloric intake is insufficient, when vigorous exercise is not supplemented by caloric intake, or when other hypoglycemic agents (sulfonylureas, insulin, etc.) or alcohol are administered together. In particular, hypoglycemia is likely to occur in the elderly, patients with weak or nutritional imbalances, patients with adrenal or pituitary insufficiency, or alcoholics. Hypoglycemia can be difficult to identify in elderly people and people taking β-adrenergic blocking drugs. If symptoms of hypoglycemia are recognized due to administration of this drug, sugar (sucrose) is generally administered, and if symptoms of hypoglycemia are recognized due to concurrent use with an α-glucosidase inhibitor (acarbose, voglibose), glucose is administered.
10) Failure to control blood sugar: Patients stabilized with certain diabetes treatments may temporarily fail to control blood sugar when exposed to stress such as fever, convulsions, infection, or surgery. At these times, this drug may be discontinued and temporary insulin administration may be required. This drug may be resumed after the acute crisis has resolved. The effectiveness of oral hypoglycemic agents, which lower blood sugar levels to a certain level, declines after a certain period of time in many patients. This phenomenon, which occurs due to disease progression or decreased response to the drug, is known as secondary failure and is distinct from primary failure, in which the drug is ineffective during the initial treatment period. If there has been secondary failure with this drug and sulfonylurea therapy, it may be necessary to start insulin therapy.
11) Patients with specific occupations: In rare cases, severe lactic acidosis and severe delayed hypoglycemia may occur, so caution should be exercised when administering to patients engaged in work at heights or driving a car. In addition, provide sufficient and thorough warning to patients and their families regarding lactic acidosis and hypoglycemia.
12) Patients should be informed of the potential benefits and risks of this drug and other treatment methods. Additionally, they should be informed of the importance of maintaining a diet, regular exercise plan, regular blood sugar testing, glycated hemoglobin, renal function, and hematological values.
The risk of lactic acidosis, its symptoms and possible predispositions should be explained to the patient. If unexplained hyperventilation, muscle pain, fatigue, abnormal confusion, or other unspecified symptoms occur, stop taking this medication immediately and notify your medical staff.
Advise patients about the risks of excessive alcohol consumption, whether acute or chronic, while taking this medicine.
Combining this drug with oral sulfonylureas may cause hypoglycemia, but this drug alone usually does not cause acute hypoglycemia. At the beginning of combination therapy, the risk of hypoglycemia, symptoms and treatment, and conditions that may occur should be explained to the patient.
13) It has been reported that the administration of oral hypoglycemic agents is associated with an increase in cardiovascular mortality compared to diet alone or combination treatment of diet and insulin. This warning is based on a study conducted by the University Group Diabetes Program (UGDP) to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with type 2 diabetes. The UGDP reported that the cardiovascular mortality rate in patients who received diet therapy and a prescribed dose of tolbutamide (1.5 g/day) or diet therapy and a prescribed dose of phenpolmine (100 mg/day) for 5 to 8 years was approximately 2.5 times that of patients who only administered diet therapy, resulting in discontinuation of treatment in both treatment groups. Despite objections to the interpretation of these results, the results of the UGDP study provide a reasonable basis for this warning. Patients should be informed of the potential benefits and risks of this drug and other forms of treatment. Although this study included only one drug from the sulfonylurea class (tolbutamide) and one drug from the biguanide class (phenpolmine), it should be taken into account that this warning can also be applied to other related hypoglycemic agents in light of the similarities in the mechanism of action and chemical structure of each class of drugs.
14) Response to all diabetes treatments should be monitored by regularly measuring fasting blood sugar and glycated hemoglobin levels with the aim of lowering the levels to the normal range. Initially, fasting blood glucose can be used to determine treatment response. Therefore, both blood sugar and glycated hemoglobin should be monitored. Glycosylated hemoglobin levels are particularly useful in assessing long-term control.
15) Initial and regular monitoring of hematological values (e.g. hemoglobin/hematocrit, red blood cell index) and renal function (serum creatinine) should be performed at least once a year. Megaloblastic anemia is rarely observed during treatment with this drug, and if suspected, the possibility of vitamin B12 deficiency should be checked.
16) Children and adolescents
Before starting metformin treatment, it should be determined whether the patient has type 2 diabetes. Controlled clinical trials lasting one year have shown that metformin does not affect growth and sexual maturation, but there are no long-term studies on these specific points. Therefore, it is recommended to carefully monitor the effect of metformin on these parameters when treating children, especially prepubescent children, with this drug.
Children aged 10 to 12 years
Only 15 children aged 10 to 12 years participated in the controlled clinical trial in children and adolescents. Although the efficacy and safety of metformin in children under 12 years of age were not different from those in children over 12 years of age, special caution is recommended when prescribing metformin to children aged 10 to 12 years.
6. Interaction
1) Since the blood sugar lowering effect may be enhanced or reduced by combined use with the following drugs, when used together, administer while carefully observing the blood sugar level and the condition of other patients.
- Drugs that enhance blood sugar lowering action
Insulin preparations, sulfonamide and sulfonylurea drugs, α-glucosidase inhibitors, anabolic steroids, guanethidine, salicylates (aspirin, etc.), β-blockers (propranolol, etc.), MAO inhibitors
- Drugs that reduce blood sugar lowering action
Epinephrine, sympathomimetics, corticosteroids, thyroid hormones, follicular hormones, estrogens, oral contraceptives, thiazide and other diuretics, pyrazinamide, isoniazid, nicotinic acid, phenothiazines, phenytoin, calcium channel antagonists.
2) Alcohol: The risk of lactic acidosis increases during the acute alcohol intoxication period, especially in the following circumstances.
- Hungry or malnutrition
- Liver dysfunction
You should avoid drinking alcohol and taking drugs that contain alcohol.
3) Iodine-labeled contrast media: Renal failure may occur in association with intravenous administration of iodine-labeled contrast media, which may lead to accumulation of metformin and potentially expose patients to the risk of lactic acidosis. Metformin should be discontinued before or at the time of testing with iodine-labeled contrast media, and treatment should be resumed only after at least 48 hours and after reassessment of renal function and determination that there is no risk of further damage. (Refer to 2. Do not administer to the following patients.)
4) Glyburide: In a single-dose study on patients with type 2 diabetes, co-administration of this drug and glyburide did not change the pharmacokinetics or pharmacodynamic properties of this drug. A decrease in the AUC and Cmax of glyburide was observed, but the deviation was large. The lack of correlation between blood concentrations and pharmacokinetic effects of a single dose of this drug in this study indicates that the clinical significance of this interaction is unclear.
5) Furosemide: A study on the drug interaction between this drug and furosemide as a single dose in healthy people showed that the pharmacokinetic values of each substance were affected by co-administration. Furosemide increases the plasma concentration of this drug without significant changes in its renal clearance, increasing blood Cmax by 22% and blood AUC by 15%. When administered together with this drug, the Cmax and AUC of furosemide are reduced by 31% and 12%, respectively, compared to single administration, and the terminal half-life of furosemide is reduced by 32% without changing the renal clearance of furosemide. There is no available information regarding the interaction when this drug is co-administered with furosemide chronically.
6) Nifedipine: A study on the drug interaction between this drug and nifedipine in a single dose in normal healthy volunteers showed that co-administration with nifedipine increases the Cmax and AUC of this drug in plasma by 20% and 9%, respectively, and increases urinary excretion. Tmax and half-life are not affected. Nifedipine enhances the absorption of this drug. This drug does not significantly affect nifedipine.
7) Drugs that may affect this drug, such as cationic drugs that may affect renal function, cause significant hemodynamic changes, or are excreted through renal tubular secretion: Metformin is a substrate of the organic cation transporter (OCT) OCT1 and OCT2.
- When used in combination with OCT1 inhibitors (verapamil, etc.), the efficacy of metformin may be reduced.
- When used in combination with OCT1 inducers (rifampicin, etc.), the gastrointestinal absorption and efficacy of metformin may increase.
- When used in combination with OCT2 inhibitors (cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, etc.), the renal excretion of metformin may be reduced and the blood concentration of metformin may increase.
- When used in combination with OCT2 and OCT1 simultaneous inhibitors (crizotinib, olaparib), the renal excretion and efficacy of metformin may be affected.
Therefore, when metformin and these drugs are administered together, the blood concentration of metformin may increase, so caution is needed, especially in patients with renal impairment. Because OCT inhibitors/inducers may change the efficacy of metformin, dose adjustment of metformin may be considered if necessary.
In addition, nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-II (Cyclo-oxygenase) inhibitors, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor antagonists, and diuretics (especially loop diuretics) may have an adverse effect on renal function and increase the risk of lactic acidosis. Therefore, renal function should be carefully monitored when administered in combination with metformin. Must observe.
8) Others: In single-dose co-administration studies in healthy volunteers, the pharmacokinetic properties of this drug and propranolol, and this drug and ibuprofen were not affected by each other.
The drug's binding to plasma proteins is negligible, so compared to sulfonylureas that bind extensively to plasma proteins, it has little interaction with drugs that bind to proteins in large quantities, such as salicylates, sulfonamides, chloramphenicol, and probenecid.
7. Administration to pregnant women
Uncontrolled hyperglycemia in the periconceptional phase and during pregnancy is associated with an increased risk of congenital abnormalities, miscarriage, pregnancy-induced hypertension, preeclampsia, and perinatal mortality. It is important to keep blood sugar levels as close to normal as possible throughout pregnancy to reduce the risks associated with high blood sugar during pregnancy.
Metformin crosses the placenta, and levels of transplacental passage can be as high as maternal concentrations.
Data from multiple studies (clinical studies, register-based cohort studies, meta-analyses, etc.) on metformin use in the periconceptional phase and during pregnancy (over 1000 exposures) have not identified an increased risk of congenital anomalies and/or fetal/neonatal toxicity due to metformin exposure during the periconceptional phase and/or pregnancy.
Babies exposed to metformin in utero may be small for gestational age. There is limited evidence on the effects of metformin on long-term birth weight outcomes and metabolic complications in infants. It does not appear to affect motor-social development up to 4 years of age, but results beyond 4 years of age are limited.
If you are planning to become pregnant or are clinically necessary for the purpose of controlling blood sugar levels during pregnancy, the use of metformin may be considered in addition to or as an alternative to insulin.
However, pregnant women at risk for placental insufficiency, preeclampsia, or intrauterine growth retardation should not begin treatment with metformin. Fetal development should be closely monitored to prevent birth weight loss, and metformin administration should be discontinued if fetal growth retardation is confirmed.
8. Administration to nursing mothers
This drug is excreted in breast milk and no adverse reactions have been reported in neonates/infants. However, because reported study results are limited, breastfeeding is not recommended during treatment with this drug. Considering the benefits of breastfeeding, the importance of the drug to the nursing mother, and the potential risk of adverse reactions in the infant, a decision should be made whether to discontinue breastfeeding or drug treatment.
9. Administration to children
A controlled clinical trial in pediatric diabetic patients aged 10 to 16 years for one year showed a blood sugar control effect similar to that seen in adults.
10. Administration to elderly people
Since aging is associated with a decline in renal function in the elderly, the minimum dose that achieves appropriate blood sugar control effects should be set based on the patient's renal function. Elderly patients should regularly monitor their renal function, and the maximum dose of this drug is generally not administered to elderly patients.
11. Treatment in case of overdose
Even if this drug is administered up to 85g, hypoglycemia does not occur even if lactic acidosis occurs under these conditions. The drug is dialyzed under good hemodynamic conditions with clearance rates up to 170 mL/min. Therefore, hemodialysis may be useful to remove accumulated drug in patients suspected of overdosing with this drug.
13. Others
1) This drug does not exhibit pharmacokinetic properties that cause primary or secondary regeneration or addiction.
2) Long-term carcinogenicity tests were conducted on rats (dose lasting 104 weeks) and mice (lasting 91 weeks) at doses of 900mg/Kg/day and 1500mg/Kg/day, respectively. This dose is approximately three times the human body's maximum daily allowance based on body surface area. There was no evidence of carcinogenicity associated with this drug in either male or female mice. Similarly, there was no tumorigenic potential for this drug in male rats. However, an increase in benign interstitial uterine polyps was observed in female rats administered at 900 mg/Kg/day.
There was no evidence of the mutagenic potential of this drug in reverse mutation testing (S. typhimurim), genetic mutation testing (mouse lymphoma cells), chromosomal aberration testing (human lymphocytes), or in vivo micronucleus testing (mouse bone marrow cells).
The fertility of male and female rats was not affected by this drug when administered at a high dose of 600 mg/Kg/day, or approximately twice the maximum allowable dose based on body surface area.
3) For patients who have difficulty swallowing this medicine, divide it in half using a dividing line and then take it. (Limited to 1000 mg of Glucopar)
4) Effect on body weight: Compared to other commonly used hypoglycemic agents (sulfonylureas, thiazolinediones, etc.), this drug is beneficial in the treatment of type 2 diabetes patients as it does not cause weight gain. Maintain or lose weight to limit other risk factors associated with weight gain. Long-term use provides more stable blood sugar control and reduces the risk of diabetes complications. In clinical trials in adults and children, this drug improved blood sugar control without weight gain or with slight weight loss.
14. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
500 tablets/bottle
7. Period of use
36 months from date of manufacture
1 tablet
- Active ingredient: Metformin hydrochloride (EP)----500mg
- Additives: Methacrylic acid/ethyl acrylate copolymer (Eudragit L30D-55), triethyl citrate, povidone, magnesium stearate
2. Effectiveness
• Treatment of type 2 diabetes patients whose blood sugar levels are inadequately controlled through diet and exercise therapy. (Especially in overweight diabetic patients)
In adults, this drug can be used as monotherapy or in combination with other oral hypoglycemic agents or insulin.
• In children over 10 years of age and growing adolescents, this drug can be used as monotherapy or in combination with insulin.
3. Dosage and dosage
adult
The administered dose should be determined for each individual based on drug effectiveness and tolerability, and should not exceed the recommended maximum daily dose.
This drug must be administered at a low dose in order to reduce adverse reactions in the gastrointestinal tract and confirm the minimum dose necessary for proper blood sugar control. Administer 500 mg 2-3 times a day, once with meals. The dosage is gradually increased by 500 mg every week, and when taking up to 2000 mg, it is usually divided into two times a day, in the morning and evening. If the dose exceeds 2000 mg, it can be divided into 3 doses per day and administered with meals, up to a maximum of 2550 mg per day.
When starting medication and adjusting the dose, fasting blood sugar should be measured to measure the therapeutic response to this drug and to confirm the minimum effective dose. The concentration of glycated hemoglobin in the blood should be measured at approximately 3-month intervals.
The treatment goal of this drug is to reduce fasting blood sugar and blood glycated hemoglobin concentration to normal or close to normal levels by administering it at the minimum effective dose when administered as monotherapy or in combination with sulfonylureas or insulin.
In general, if a patient whose blood sugar is controlled through diet alone temporarily loses control of blood sugar, a short-term administration of this drug may be sufficient to achieve sufficient effect.
Children and adolescents
This medicine can be used in children over 10 years of age or growing adolescents.
The typical starting dose is 500 milligrams once daily, administered during or after a meal.
After a week, blood sugar levels should be measured and the dosage adjusted. Gastrointestinal side effects can be improved with gradual dose increase. The maximum daily dose is 2000mg. Divide the dose into 2 to 3 doses.
patients with renal impairment
This drug can be used by adjusting the dose as follows among patients with stage 3a moderate renal impairment (creatinine clearance [CrCl] 45≤~<60ml/min or glomerular filtration rate (GFR) 45≤~<60mL/min/1.73㎡) who are not accompanied by other symptoms that may increase the risk of lactic acidosis.
- The starting dose is 500mg or 850mg once a day. The maximum daily dose is 1000 mg, divided into two doses. Renal function should be closely monitored every 3-6 months. If creatinine clearance or glomerular filtration rate decreases below 45ml/min or 45ml/min/1.73㎡, administration of this drug should be discontinued immediately.
4. Precautions for use
1. Warning
It may cause severe lactic acidosis or hypoglycemia. Cases of death due to lactic acidosis have been reported.
2. Do not administer to the following patients.
1) Patients with moderate (stage3b) and severe renal impairment (creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.73m2), acute conditions that may affect renal function such as dehydration, serious infection, cardiovascular collapse (shock), acute myocardial infarction, and sepsis.
2) Patients with acute and unstable heart failure
3) Patients receiving tests that involve intravenous administration of radioiodine contrast material (e.g. intravenous urography, intravenous cholangiography, angiography, computed tomography using contrast media, etc.) (can cause acute renal failure, and are associated with lactic acidosis in patients receiving this drug. Therefore, among patients scheduled for such tests, if the glomerular filtration rate is >60ml/min/1.73m2, at least at the time of the test or in advance The drug must be discontinued, and re-administration is not possible within 48 hours. In patients with moderate renal impairment (glomerular filtration rate 45 to 60 ml/min/1.73 m2), re-administration is not possible within 48 hours after renal function is re-evaluated. Treatment is resumed only after this.)
4) Patients with a history of hypersensitivity to this drug or biguanide drugs
5) Patients with acute or chronic metabolic acidosis, including type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis [Type 1 diabetes and diabetic ketoacidosis are treated with insulin.]
6) Diabetic precoma
7) In patients with severe infections or severe traumatic systemic disorders, treatment with this drug should be temporarily stopped and treatment should be restarted when the patient's oral intake is restored and renal function is found to be normal.
8) In the case of surgical procedures (excluding minor surgeries where there are no restrictions on food and fluid intake), this drug should be temporarily stopped 48 hours before surgery, and treatment should be restarted at least 48 hours after renal function is confirmed to be normal.
9) Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal dysfunction
10) Hepatic dysfunction (since impaired liver function is associated with some cases of lactic acidosis, administration of this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease), pulmonary infarction, patients with severe pulmonary dysfunction and other conditions prone to hypoxemia, excessive alcohol intake, and patients with gastrointestinal disorders such as dehydration, diarrhea, and vomiting.
11) Pregnant women at risk of placental insufficiency, preeclampsia, and intrauterine growth retardation (refer to section 7. Administration for pregnant women)
3. Administer with caution to the following patients:
(There is a possibility of lactic acidosis and hypoglycemia.)
1) Irregular meals, insufficient meal intake
2) Intense muscle exercise
3) Patients taking interacting drugs
4. Adverse reactions
1) Lactic acidosis: Lactic acidosis is very rare but serious, and is a metabolic complication that occurs due to accumulation of this drug during treatment. In 50% of cases it occurs, it is fatal. Lactic acidosis occurs frequently in acute renal dysfunction, cardiopulmonary disease, and sepsis. Lactic acidosis may occur when there is significant tissue hypoperfusion and hypoxia and in conjunction with pathophysiological conditions, including diabetes. Lactic acidosis is characterized by increased blood lactic acid concentration (over 5 mmol/L), decreased blood pH, electrolyte imbalance with increased difference between anions, and increased lactic acid/pyruvate ratio. If this drug is believed to be the cause of lactic acidosis, the blood concentration of this drug is generally found to exceed 5 μg/mL.
There are very few reports of the development of lactic acidosis in patients receiving this drug (approximately 0.03 cases per 1,000 patients per year, and approximately 0.015 fatal cases per 1,000 patients per year). The reported cases primarily occurred in diabetic patients with significantly reduced renal function, including intrinsic renal disease and renal hypoperfusion, in conditions such as multiple medical and surgical problems and combined administration of many drugs. The risk of lactic acidosis increases with the degree of renal function decline and the patient's age.
In addition, this drug should be discontinued immediately if symptoms related to hypoxia, dehydration, or sepsis appear. If liver function is impaired, the ability to excrete lactic acid may be significantly reduced, so this drug is generally not administered to patients with clinical or laboratory findings of liver disease. Since alcohol may cause this drug to affect lactic acid metabolism, acute or chronic excessive intake of alcohol should be avoided while taking this drug.
The onset of lactic acidosis is sometimes difficult to distinguish and is accompanied by nonspecific symptoms such as malaise, myalgia, dyspnea, asthenia, and abdominal pain. If acidosis becomes more severe, a drop in body temperature, hypotension, and resistant bradyarrhythmia may occur. Patients and doctors should be aware of the importance of these symptoms, and patients should notify their doctors immediately if these symptoms occur. Serum electrolytes, ketones, blood sugar, blood pH (<7.35), lactic acid concentration, and blood concentration of this drug may also be useful in confirming lactic acidosis. Additionally, if there is a high suspicion of lactic acidosis, necessary measures are taken without expecting a lactic acid measurement result. In particular, be careful because lactic acidosis is likely to occur when the initial dose is increased. Gastrointestinal symptoms are common in the early stages of treatment once the patient has stabilized on a specific dose of this drug, but later gastrointestinal symptoms may be due to lactic acidosis or another serious illness.
Fasting venous plasma lactate concentrations above the upper limit of normal but below 5 mmol/L in patients receiving this drug do not indicate impending lactic acidosis and may be due to other mechanisms such as poorly controlled diabetes or obesity, excessive physical activity, or technical problems in handling the specimen. Lactic acidosis should be suspected in diabetic patients presenting with metabolic acidosis without evidence of ketoacidosis (ketonuria and ketonemia).
Lactic acidosis is a medical emergency requiring hospitalization. If lactic acidosis occurs in a patient taking this drug, the drug should be discontinued immediately and general supportive treatment should be administered immediately. Since the drug is dialyzable (clearance up to 170 mL/min in good hemodynamic conditions), immediate hemodialysis is recommended to normalize acidosis and remove accumulated drug. This treatment sometimes results in immediate symptom improvement and recovery.
2) Digestive system: Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal distension, loss of appetite, indigestion, constipation, abdominal pain) are the most common reactions that occur when taking this drug, and especially in the early stages of treatment, they occur about 30% more frequently in the group administered with this drug alone than in the placebo administered group. These symptoms are usually temporary and will disappear on their own while treatment continues. Sometimes, a temporary dose reduction may be useful. In clinical trials, approximately 4% of patients discontinued this drug due to gastrointestinal reactions.
Since gastrointestinal symptoms occur in a dose-related manner during the initial phase of treatment, they can be reduced by gradually increasing the dose or by administering this drug with meals.
Severe diarrhea and/or vomiting may cause dehydration and prerenal azotemia and should be temporarily discontinued under these conditions. In patients who have been stabilized on this drug, non-specific gastrointestinal symptoms may not be due to treatment but may be due to concurrent disease or lactic acidosis.
3) Sensory system: During the initial stage of treatment, approximately 3% of patients complain of an unpleasant or metallic taste, which usually disappears gradually.
4) Skin: A rash may occur, so discontinue administration in this case.
5) Blood system: In rare cases, anemia, decreased white blood cells, and decreased platelets may occur. Vitamin B12 deficiency is common.
6) Liver: Occasionally liver dysfunction may occur.
7) Hypoglycemia: In rare cases, severe delayed hypoglycemia may occur.
8) Adverse reactions in children: Adverse reactions reported in clinical trials in which metformin was administered to a small pediatric cohort of patients aged 10 to 16 years for 1 year, as well as in published and post-marketing surveillance results, were similar to those reported in adults in terms of their characteristics and severity.
5. General precautions
1) Monitoring of renal function: This drug is mostly excreted by the kidneys, and the risk of accumulation of this drug and lactic acidosis increases depending on the degree of renal function impairment. Glomerular filtration rate should be evaluated before starting treatment and periodically thereafter. Patients with normal renal function should have a renal function test checked at least once a year. Patients with a creatinine clearance lower than normal and the elderly should have a renal function test performed at least 2 to 4 times a year. If the creatinine clearance rate is <45ml/min (glomerular filtration rate <45ml/min/1.73m2), discontinue treatment with this drug. Special caution is needed in situations that may result in rapid renal function impairment, such as when there are symptoms of dehydration (severe or persistent vomiting or diarrhea) or when starting medications that affect renal function (such as antihypertensive drugs or diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs)). In these acute situations, metformin should be discontinued immediately and temporarily.
2) Diabetes-like symptoms: Consider application only to patients with an established diagnosis of diabetes. Be aware that in addition to diabetes, there are diseases with diabetes-like symptoms such as abnormal glucose tolerance and positive urine glucose (nephrogenic diabetes, geriatric glucose metabolism abnormalities, thyroid dysfunction, etc.).
3) Adjustment during administration: In cases where administration is no longer necessary, when a reduction is necessary, or when the effect becomes ineffective or insufficient due to the patient's deterioration, complications of infection, etc., pay attention to meal intake, weight change, blood sugar level, presence or absence of infection, etc., and pay attention to whether to continue administration, dosage, and selection of drug.
4) Hypoxic state: Cardiovascular collapse (shock) of any cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxia are associated with lactic acidosis and may cause prerenal azotemia. If this occurs in a patient receiving treatment with this drug, administration of this drug should be discontinued immediately.
5) Cardiac function: Patients with heart failure have a higher risk of hypoxia and decreased renal function. For patients with stable chronic heart failure, metformin can be administered with regular monitoring of heart and kidney function.
6) Alcohol intake: Alcohol is known to increase the effect of this drug on lactic acid metabolism. Therefore, acute or chronic excessive intake of alcohol should be avoided while taking this medicine.
7) Vitamin B12 level: It is recommended to monitor serum vitamin B12 level annually. The risk of low vitamin B12 levels increases in patients with higher metformin doses, longer treatment duration, and/or with risk factors known to cause vitamin B12 deficiency.
8) Changes in controlled diabetic patients: If a patient whose type 2 diabetes was previously well controlled with this drug develops abnormal laboratory findings or clinical disease (especially vague and poorly defined disease), the patient should be immediately evaluated for the development of ketoacidosis or lactic acidosis. Serum electrolytes, ketones, and blood sugar levels are tested, and if necessary, blood pH, lactate, pyruvate, and drug levels are tested. If any form of acidosis appears, immediately stop administering this drug and take other appropriate and correct measures.
9) Hypoglycemia: Hypoglycemia does not occur in patients who take this drug alone under normal use conditions, but occurs when caloric intake is insufficient, when vigorous exercise is not supplemented by caloric intake, or when other hypoglycemic agents (sulfonylureas, insulin, etc.) or alcohol are administered together. In particular, hypoglycemia is likely to occur in the elderly, patients with weak or nutritional imbalances, patients with adrenal or pituitary insufficiency, or alcoholics. Hypoglycemia can be difficult to identify in elderly people and people taking β-adrenergic blocking drugs. If symptoms of hypoglycemia are recognized due to administration of this drug, sugar (sucrose) is generally administered, and if symptoms of hypoglycemia are recognized due to concurrent use with an α-glucosidase inhibitor (acarbose, voglibose), glucose is administered.
10) Failure to control blood sugar: Patients stabilized with certain diabetes treatments may temporarily fail to control blood sugar when exposed to stress such as fever, convulsions, infection, or surgery. At these times, this drug may be discontinued and temporary insulin administration may be required. This drug may be resumed after the acute crisis has resolved. The effectiveness of oral hypoglycemic agents, which lower blood sugar levels to a certain level, declines after a certain period of time in many patients. This phenomenon, which occurs due to disease progression or decreased response to the drug, is known as secondary failure and is distinct from primary failure, in which the drug is ineffective during the initial treatment period. If there has been secondary failure with this drug and sulfonylurea therapy, it may be necessary to start insulin therapy.
11) Patients with specific occupations: In rare cases, severe lactic acidosis and severe delayed hypoglycemia may occur, so caution should be exercised when administering to patients engaged in work at heights or driving a car. In addition, provide sufficient and thorough warning to patients and their families regarding lactic acidosis and hypoglycemia.
12) Patients should be informed of the potential benefits and risks of this drug and other treatment methods. Additionally, they should be informed of the importance of maintaining a diet, regular exercise plan, regular blood sugar testing, glycated hemoglobin, renal function, and hematological values.
The risk of lactic acidosis, its symptoms and possible predispositions should be explained to the patient. If unexplained hyperventilation, muscle pain, fatigue, abnormal confusion, or other unspecified symptoms occur, stop taking this medication immediately and notify your medical staff.
Advise patients about the risks of excessive alcohol consumption, whether acute or chronic, while taking this medicine.
Combining this drug with oral sulfonylureas may cause hypoglycemia, but this drug alone usually does not cause acute hypoglycemia. At the beginning of combination therapy, the risk of hypoglycemia, symptoms and treatment, and conditions that may occur should be explained to the patient.
13) It has been reported that the administration of oral hypoglycemic agents is associated with an increase in cardiovascular mortality compared to diet alone or combination treatment of diet and insulin. This warning is based on a study conducted by the University Group Diabetes Program (UGDP) to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with type 2 diabetes. The UGDP reported that the cardiovascular mortality rate in patients who received diet therapy and a prescribed dose of tolbutamide (1.5 g/day) or diet therapy and a prescribed dose of phenpolmine (100 mg/day) for 5 to 8 years was approximately 2.5 times that of patients who only administered diet therapy, resulting in discontinuation of treatment in both treatment groups. Despite objections to the interpretation of these results, the results of the UGDP study provide a reasonable basis for this warning. Patients should be informed of the potential benefits and risks of this drug and other forms of treatment. Although this study included only one drug from the sulfonylurea class (tolbutamide) and one drug from the biguanide class (phenpolmine), it should be taken into account that this warning can also be applied to other related hypoglycemic agents in light of the similarities in the mechanism of action and chemical structure of each class of drugs.
14) Response to all diabetes treatments should be monitored by regularly measuring fasting blood sugar and glycated hemoglobin levels with the aim of lowering the levels to the normal range. Initially, fasting blood glucose can be used to determine treatment response. Therefore, both blood sugar and glycated hemoglobin should be monitored. Glycosylated hemoglobin levels are particularly useful in assessing long-term control.
15) Initial and regular monitoring of hematological values (e.g. hemoglobin/hematocrit, red blood cell index) and renal function (serum creatinine) should be performed at least once a year. Megaloblastic anemia is rarely observed during treatment with this drug, and if suspected, the possibility of vitamin B12 deficiency should be checked.
16) Children and adolescents
Before starting metformin treatment, it should be determined whether the patient has type 2 diabetes. Controlled clinical trials lasting one year have shown that metformin does not affect growth and sexual maturation, but there are no long-term studies on these specific points. Therefore, it is recommended to carefully monitor the effect of metformin on these parameters when treating children, especially prepubescent children, with this drug.
Children aged 10 to 12 years
Only 15 children aged 10 to 12 years participated in the controlled clinical trial in children and adolescents. Although the efficacy and safety of metformin in children under 12 years of age were not different from those in children over 12 years of age, special caution is recommended when prescribing metformin to children aged 10 to 12 years.
6. Interaction
1) Since the blood sugar lowering effect may be enhanced or reduced by combined use with the following drugs, when used together, administer while carefully observing the blood sugar level and the condition of other patients.
- Drugs that enhance blood sugar lowering action
Insulin preparations, sulfonamide and sulfonylurea drugs, α-glucosidase inhibitors, anabolic steroids, guanethidine, salicylates (aspirin, etc.), β-blockers (propranolol, etc.), MAO inhibitors
- Drugs that reduce blood sugar lowering action
Epinephrine, sympathomimetics, corticosteroids, thyroid hormones, follicular hormones, estrogens, oral contraceptives, thiazide and other diuretics, pyrazinamide, isoniazid, nicotinic acid, phenothiazines, phenytoin, calcium channel antagonists.
2) Alcohol: The risk of lactic acidosis increases during the acute alcohol intoxication period, especially in the following circumstances.
- Hungry or malnutrition
- Liver dysfunction
You should avoid drinking alcohol and taking drugs that contain alcohol.
3) Iodine-labeled contrast media: Renal failure may occur in association with intravenous administration of iodine-labeled contrast media, which may lead to accumulation of metformin and potentially expose patients to the risk of lactic acidosis. Metformin should be discontinued before or at the time of testing with iodine-labeled contrast media, and treatment should be resumed only after at least 48 hours and after reassessment of renal function and determination that there is no risk of further damage. (Refer to 2. Do not administer to the following patients.)
4) Glyburide: In a single-dose study on patients with type 2 diabetes, co-administration of this drug and glyburide did not change the pharmacokinetics or pharmacodynamic properties of this drug. A decrease in the AUC and Cmax of glyburide was observed, but the deviation was large. The lack of correlation between blood concentrations and pharmacokinetic effects of a single dose of this drug in this study indicates that the clinical significance of this interaction is unclear.
5) Furosemide: A study on the drug interaction between this drug and furosemide as a single dose in healthy people showed that the pharmacokinetic values of each substance were affected by co-administration. Furosemide increases the plasma concentration of this drug without significant changes in its renal clearance, increasing blood Cmax by 22% and blood AUC by 15%. When administered together with this drug, the Cmax and AUC of furosemide are reduced by 31% and 12%, respectively, compared to single administration, and the terminal half-life of furosemide is reduced by 32% without changing the renal clearance of furosemide. There is no available information regarding the interaction when this drug is co-administered with furosemide chronically.
6) Nifedipine: A study on the drug interaction between this drug and nifedipine in a single dose in normal healthy volunteers showed that co-administration with nifedipine increases the Cmax and AUC of this drug in plasma by 20% and 9%, respectively, and increases urinary excretion. Tmax and half-life are not affected. Nifedipine enhances the absorption of this drug. This drug does not significantly affect nifedipine.
7) Drugs that may affect this drug, such as cationic drugs that may affect renal function, cause significant hemodynamic changes, or are excreted through renal tubular secretion: Metformin is a substrate of the organic cation transporter (OCT) OCT1 and OCT2.
- When used in combination with OCT1 inhibitors (verapamil, etc.), the efficacy of metformin may be reduced.
- When used in combination with OCT1 inducers (rifampicin, etc.), the gastrointestinal absorption and efficacy of metformin may increase.
- When used in combination with OCT2 inhibitors (cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, etc.), the renal excretion of metformin may be reduced and the blood concentration of metformin may increase.
- When used in combination with OCT2 and OCT1 simultaneous inhibitors (crizotinib, olaparib), the renal excretion and efficacy of metformin may be affected.
Therefore, when metformin and these drugs are administered together, the blood concentration of metformin may increase, so caution is needed, especially in patients with renal impairment. Because OCT inhibitors/inducers may change the efficacy of metformin, dose adjustment of metformin may be considered if necessary.
In addition, nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-II (Cyclo-oxygenase) inhibitors, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor antagonists, and diuretics (especially loop diuretics) may have an adverse effect on renal function and increase the risk of lactic acidosis. Therefore, renal function should be carefully monitored when administered in combination with metformin. Must observe.
8) Others: In single-dose co-administration studies in healthy volunteers, the pharmacokinetic properties of this drug and propranolol, and this drug and ibuprofen were not affected by each other.
The drug's binding to plasma proteins is negligible, so compared to sulfonylureas that bind extensively to plasma proteins, it has little interaction with drugs that bind to proteins in large quantities, such as salicylates, sulfonamides, chloramphenicol, and probenecid.
7. Administration to pregnant women
Uncontrolled hyperglycemia in the periconceptional phase and during pregnancy is associated with an increased risk of congenital abnormalities, miscarriage, pregnancy-induced hypertension, preeclampsia, and perinatal mortality. It is important to keep blood sugar levels as close to normal as possible throughout pregnancy to reduce the risks associated with high blood sugar during pregnancy.
Metformin crosses the placenta, and levels of transplacental passage can be as high as maternal concentrations.
Data from multiple studies (clinical studies, register-based cohort studies, meta-analyses, etc.) on metformin use in the periconceptional phase and during pregnancy (over 1000 exposures) have not identified an increased risk of congenital anomalies and/or fetal/neonatal toxicity due to metformin exposure during the periconceptional phase and/or pregnancy.
Babies exposed to metformin in utero may be small for gestational age. There is limited evidence on the effects of metformin on long-term birth weight outcomes and metabolic complications in infants. It does not appear to affect motor-social development up to 4 years of age, but results beyond 4 years of age are limited.
If you are planning to become pregnant or are clinically necessary for the purpose of controlling blood sugar levels during pregnancy, the use of metformin may be considered in addition to or as an alternative to insulin.
However, pregnant women at risk for placental insufficiency, preeclampsia, or intrauterine growth retardation should not begin treatment with metformin. Fetal development should be closely monitored to prevent birth weight loss, and metformin administration should be discontinued if fetal growth retardation is confirmed.
8. Administration to nursing mothers
This drug is excreted in breast milk and no adverse reactions have been reported in neonates/infants. However, because reported study results are limited, breastfeeding is not recommended during treatment with this drug. Considering the benefits of breastfeeding, the importance of the drug to the nursing mother, and the potential risk of adverse reactions in the infant, a decision should be made whether to discontinue breastfeeding or drug treatment.
9. Administration to children
A controlled clinical trial in pediatric diabetic patients aged 10 to 16 years for one year showed a blood sugar control effect similar to that seen in adults.
10. Administration to elderly people
Since aging is associated with a decline in renal function in the elderly, the minimum dose that achieves appropriate blood sugar control effects should be set based on the patient's renal function. Elderly patients should regularly monitor their renal function, and the maximum dose of this drug is generally not administered to elderly patients.
11. Treatment in case of overdose
Even if this drug is administered up to 85g, hypoglycemia does not occur even if lactic acidosis occurs under these conditions. The drug is dialyzed under good hemodynamic conditions with clearance rates up to 170 mL/min. Therefore, hemodialysis may be useful to remove accumulated drug in patients suspected of overdosing with this drug.
13. Others
1) This drug does not exhibit pharmacokinetic properties that cause primary or secondary regeneration or addiction.
2) Long-term carcinogenicity tests were conducted on rats (dose lasting 104 weeks) and mice (lasting 91 weeks) at doses of 900mg/Kg/day and 1500mg/Kg/day, respectively. This dose is approximately three times the human body's maximum daily allowance based on body surface area. There was no evidence of carcinogenicity associated with this drug in either male or female mice. Similarly, there was no tumorigenic potential for this drug in male rats. However, an increase in benign interstitial uterine polyps was observed in female rats administered at 900 mg/Kg/day.
There was no evidence of the mutagenic potential of this drug in reverse mutation testing (S. typhimurim), genetic mutation testing (mouse lymphoma cells), chromosomal aberration testing (human lymphocytes), or in vivo micronucleus testing (mouse bone marrow cells).
The fertility of male and female rats was not affected by this drug when administered at a high dose of 600 mg/Kg/day, or approximately twice the maximum allowable dose based on body surface area.
3) For patients who have difficulty swallowing this medicine, divide it in half using a dividing line and then take it. (Limited to 1000 mg of Glucopar)
4) Effect on body weight: Compared to other commonly used hypoglycemic agents (sulfonylureas, thiazolinediones, etc.), this drug is beneficial in the treatment of type 2 diabetes patients as it does not cause weight gain. Maintain or lose weight to limit other risk factors associated with weight gain. Long-term use provides more stable blood sugar control and reduces the risk of diabetes complications. In clinical trials in adults and children, this drug improved blood sugar control without weight gain or with slight weight loss.
14. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
500 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 6items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 6 | Daimit Tab. | Precautions for use | 2026.10.02 | PDF0006_199302107_Precautions for use (Dimit tablet).pdf |
| 5 | Daimit Tab. | Precautions for use | 2023.07.21 | PDFPrecautions for use of Dymit tablets (draft).pdf |
| 4 | Daimit Tab. | Dymit tablets (precautions for use) | 2018.07.09 | PDFDymit tablets.pdf |
| 3 | Daimit Tab. | Dymit tablets (dosage, precautions for use) | 2018.01.03 | PDFMetformin hydrochloride single tablet_film-coated tablet unification adjustment plan. |
| 2 | Daimit Tab. | Dymit Tablet (Dosage) | 2010.07.14 | HWP9. Change in Daimit Tablet (Dosage and Administration) (2010.07.14).hwp |
| 1 | Daimit Tab. | Dymit tablets (efficacy, dosage, usage, precautions... | 2007.07.03 | HWP9. Daimijeong (filial piety, dragon, death) change (2007.07.03).hwp |